Evidence map›Paper›PMID 22982055›Full record

ArticleVascular pharmacology2013

Alpha(1)-adrenergic-mediated eNOS phosphorylation in intact arteries.

Robin C Looft-Wilson, Sarah E Todd, Christina A Araj, Stephanie M Mutchler, Cara A Raphael Goodell

Open access · greenAbstract read
In one paragraph

Article in Vascular pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Stimulation of AlphaPPAR research · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Activation of αBritish journal of pharmacology · 2017
    Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Robin C Looft-WilsonDepartment of Kinesiology and Health Sciences, The College of William & Mary, Williamsburg, VA 23187, United States. rlooft@wm.edu
Sarah E Todd
Christina A Araj
Stephanie M Mutchler
Cara A Raphael Goodell
Williams (United States) · USWilliam & Mary · US

Funding

Vascular cell-to-cell communication during remodelingR15HL082647 · NHLBI · COLLEGE OF WILLIAM AND MARY · PI LOOFT-WILSON, ROBIN C · 2006 to 2006
$210k
Regulation of eNOS by Shear Stress in Intact ArteriesR15HL102742 · NHLBI · COLLEGE OF WILLIAM AND MARY · PI LOOFT-WILSON, ROBIN C · 2010 to 2010
$207k
NHLBI NIH HHS 1R15HL082647NHLBI NIH HHS 1R15HL102742NHLBI NIH HHS R15 HL082647NHLBI NIH HHS R15 HL102742
6 · The paper itself

Abstract

Activation of arterial smooth muscle alpha(1)-adrenergic receptors results in vasoconstriction, as well as a secondary release of nitric oxide and slow vasodilation, presumably through gap junction communication from smooth muscle to endothelium. We hypothesized that this slow vasodilation is due to activation of eNOS through phosphorylation at Ser1179 and dephosphorylation at Thr495. Phosphorylation was measured by western blot using mouse mesenteric arteries that were cannulated and pressurized (75 mm Hg) and treated either by 1) 5 min of phenylephrine superfusion (10(-5)M) (PE5), 2) 15 min of phenylephrine (PE15), 3) 15 min phenylephrine followed by acetylcholine (10(-4)M) (PE+ACh), or 4) 20 min time control with no treatment (NT) [4-5 arteries pooled per treatment per blot; 5 blots performed]. These treatments allowed correlation between vasomotor changes, namely maximal constriction (PE5), slow vasodilation (PE15), and maximal dilation (PE+ACh), and relative phosphorylation changes. Phosphorylation of eNOS at Ser1179 was increased relative to NT by more than 2-fold at PE5 and remained similarly increased at PE15 and PE+ACh. Phosphorylation of eNOS at Thr495 was less in all treatments relative to NT, but not significantly. Treatment with L-NAME (10(-4)M) or endothelial denudation indicated that the slow dilation in response to phenylephrine was completely due to nitric oxide synthase and was endothelial dependent. These results indicate that eNOS phosphorylation at Ser1179 occurs before the slow dilation and is not actively involved in this vasodilation or dilation to acetylcholine, but may play a permissive role in eNOS activation by other mechanisms. It is not yet known what mechanism is responsible for Ser1179 phosphorylation with phenylephrine stimulation.

Indexed as

AcetylcholineAdrenergic alpha-1 Receptor AgonistsAnimalsBlotting, WesternEndothelium, VascularMaleMesenteric ArteriesMiceMice, Inbred C57BLNG-Nitroarginine Methyl EsterNitric Oxide Synthase Type IIIPhenylephrinePhosphorylationReceptors, Adrenergic, alpha-1Time FactorsVasoconstrictionAcetylcholineAdrenergic alpha-1 Receptor AgonistsNG-Nitroarginine Methyl EsterNitric Oxide Synthase Type IIIPhenylephrineReceptors, Adrenergic, alpha-1Vasoconstrictor AgentsVasodilator Agents

Identifiers

PMID22982055
PMCPMC3534816
OpenAlexW2020677655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.